Biopharma Business

The Cell and Gene Therapy Catapult (CGT Catapult) has signed a Memorandum of Understanding (MoU) with the Forum for Innovative Regenerative Medicine (FIRM) in Japan, demonstrating a shared ambition to accelerate research and commercialisation of regenerative medicine.

Through this collaboration, FIRM and CGT Catapult hope to create a cooperative relationship between major players in the UK and Japan that will lead to information sharing on regenerative medicine technologies, policies and legal issues. Additionally, both groups hope that the partnership will enable a continued increase in the profile and standing of their countries within the cell and gene therapy space, advancing both organisations places at the forefront of cell and gene therapy research globally.

“We are pleased to announce this memorandum of understanding. The agreement with FIRM will enable us to boost the reach and profile of the Cell and Gene Therapy Catapult in Japan and ultimately develop stronger links between industry in both countries,” stated Keith Thompson, CEO of the Cell and Gene Therapy Catapult.

“The partnership between the Cell and Gene Therapy Catapult and FIRM will clearly promote the collaboration of industries between the UK and Japan, and accelerate the development of regenerative and cellular medicine products not only in both countries but worldwide,” added Yuzo Toda, chairman of FIRM.

“This marks yet another relationship with an important major international institution in the cell and gene therapy space, indicating that the Cell and Gene Therapy Catapult is continuing towards its goal of becoming a global hub of expertise in this burgeoning area of Life Sciences,” concluded Thompson.